title: Altered regulation of the rostral ventrolateral medulla in hypertensive obese Zucker rats.
abstract: Obese Zucker rats (OZR) have elevated sympathetic nerve activity (SNA) and mean arterial pressure (MAP) compared with lean Zucker rats (LZR). We examined whether altered tonic glutamatergic, angiotensinergic, or GABAergic inputs to the rostral ventrolateral medulla (RVLM) contribute to elevated SNA and MAP in OZR. Male rats (14-18 wk) were anesthetized with urethane (1.5 g/kg iv), ventilated, and paralyzed to record splanchnic SNA, heart rate (HR), and MAP. Inhibition of the RVLM by microinjections of muscimol eliminated SNA and evoked greater decreases in MAP in OZR vs. LZR (P < 0.05). Antagonism of angiotensin AT(1) receptors in RVLM with losartan yielded modest decreases in SNA and MAP in OZR but not LZR (P < 0.05). However, antagonism of ionotropic glutamate receptors in RVLM with kynurenate produced comparable decreases in SNA, HR, and MAP in OZR and LZR. Antagonism of GABA(A) receptors in RVLM with gabazine evoked smaller rises in SNA, HR, and MAP in OZR vs. LZR (P < 0.05), whereas responses to microinjections of GABA into RVLM were comparable. Inhibition of the caudal ventrolateral medulla, a major source of GABA to the RVLM, evoked attenuated rises in SNA and HR in OZR (P <0.05). Likewise, inhibition of nucleus tractus solitarius, the major excitatory input to caudal ventrolateral medulla, produced smaller rises in SNA and HR in OZR. These results suggest the elevated SNA and MAP in OZR is derived from the RVLM and that enhanced angiotensinergic activation and reduced GABAergic inhibition of the RVLM may contribute to the elevated SNA and MAP in the OZR.
authors.affiliation: Dept. of Integrative Physiology, Univ. of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA.
authors.forename: Domitila A
authors.initials: DA
authors.lastname: Huber
authors.forename: Ann M
authors.initials: AM
authors.lastname: Schreihofer
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D001933:Brain Stem / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology / Q000502:physiology; D006339:Heart Rate / Q000502:physiology; D006973:Hypertension / Q000235:genetics / Q000503:physiopathology*; D019808:Losartan / Q000008:administration & dosage / Q000494:pharmacology; D008526:Medulla Oblongata / Q000473:pathology / Q000503:physiopathology*; D008845:Microinjections; D009129:Muscle Tonus / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D009765:Obesity / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D011924:Rats, Zucker; D011963:Receptors, GABA-A / Q000187:drug effects; D013152:Splanchnic Circulation / Q000502:physiology; D013564:Sympathetic Nervous System / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000502:physiology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D018691:Excitatory Amino Acid Antagonists; D018756:GABA Antagonists; D011963:Receptors, GABA-A; D000804:Angiotensin II; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D019808:Losartan